Picture Berlin Partner Bionnale the Annual Life Sciences Event 650x80px

Document › Details

AC Immune S.A.. (8/5/20). "Press Release: AC Immune Reports Q2 2020 Financial Results and Provides Business Update". Lausanne.

	Organisation	AC Immune S.A. (Nasdaq: ACIU)
	Organisation 2	Michael J. Fox Foundation for Parkinson’s Research
	Product	ACI-35.030 Alzheimer vaccine
	Product 2	SupraAntigen™ platform
	Index term	Roche–AC Immune: therapeutic antibodies, 201206– license excl for anti-Tau program for Alzheimer’s disease to Genentech

Original document
accessed by [iito] on 2020-08-05

Record changed: 2020-09-04

More documents for AC Immune S.A. (Nasdaq: ACIU)

[1] H. Lundbeck A/S. (4/8/22). "Press Release: Joerg Hornstein to Join Lundbeck as Chief Financial Officer and Head of Corporate Functions". Valby....
[2] AC Immune S.A.. (7/27/21). "Press Release: AC Immune Announces Strategic Acquisition of Industry-leading Parkinson’s Disease Vaccine Candidate and Equity Investment Led by Athos Service GmbH". Lausanne....
[3] Oxurion N.V.. (10/13/20). "Press Release: Oxurion NV Appoints Tom Graney, CFA as Chief Financial Officer". Leuven & Boston, MA....
[4] AC Immune S.A.. (3/23/20). "Press Release: AC Immune Receives Second Milestone and New Milestone to Increase the Potential Deal Value of Lilly Morphomer Tau Partnership". Lausanne....
[5] AC Immune S.A.. (9/20/19). "Press Release: AC Immune Receives First Milestone Payment from Lilly in Small Molecule Tau Morphomer Program". Lausanne....
[6] AC Immune S.A.. (9/17/19). "Press Release: AC Immune Receives Milestone Payment in Connection with Initiation of a Phase 2 Trial of Tau PET Tracer PI-2620". Lausanne....
[7] AC Immune S.A.. (9/4/19). "Press Release: AC Immune Awarded Michael J. Fox Foundation Grant to Accelerate Development of Parkinson’s Disease Diagnostic Imaging Agent". Lausanne....
[8] AC Immune S.A.. (8/12/19). "Press Release: AC Immune Announces Research Collaboration with University of Pennsylvania Focusing on Pathogenic Protein TDP-43 in Neurodegenerative Diseases". Lausanne....
[9] AC Immune S.A.. (3/21/19). "Press Release: AC Immune Reports Full-Year 2018 Financial Results and Provides Business Update". Lausanne....
[10] AC Immune S.A.. (1/30/19). "Press Release: AC Immune Reports Discontinuation of Phase III CREAD 1 and 2 Studies of Crenezumab in Alzheimer’s Disease". Lausanne....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

» top